Amgen Inc said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.
Source:: Reuters – Business News
Amgen Inc said on Monday it would buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene.
Source:: Reuters – Business News
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.